Medarex has announced a global collaboration agreement with Pfizer
that will provide for the discovery and development of up to 50
antibody products over ten years including the creation of fully
human antibody products in a variety...
Accelrys has signed a $21.5 million (€17.6 million) agreement to
merge SciTegic with one of its subsidiaries in a deal that will add
additional data analysis and mining software design capabilities to
Accelrys' extensive portfolio...
US life science company Serologicals has entered into a €167.6
million merger with cell signallin specialist Upstate, creating a
significant presence in the preclinical drug screening and target
validation market, the fastest growing...
US software systems provider, Genedata, has released the latest
version of Screener, a data analysis and management software system
for high throughput screening and compound profiling of
pharmacological properties and chemical structure,...
Germany's LION bioscience has made a foray into the market for
cheminformatics software with a new package designed to help
pharmaceutical companies identify, select and priortise compounds,
based on data emerging from the medicinal...
Technology holding company Coastal Holdings, has purchased a
significant equity interest in another biotechnology business,
adding to its portfolio of acquisitions and investments in the
biotechnology and nanotechnology fields.
A unique approach to microdosing, providing drug data ahead of
schedule and with improved accuracy, could herald a new era in drug
development in which human ADME data is involved in candidate
selection or deselection.
UK biotechnology company CellFactors has entered administration
following its failure to raise additional funds to further develop
its product Skeletex, a biological matrix derived from human cells
that induces new vascularised bone...
Drug discovery company Ablynx is to enter into a partnership with
Proctor and Gamble Pharmaceuticals. The agreement will make use of
Ablynx's Nanobody platform to develop drug candidates against a
G-protein coupled receptor (GPCR)...
Drug development company Jerini has transferred its peptide
technologies business unit to a wholly owned subsidiary which will
continue to provide and develop peptide-based services and products
for biomedical research.